Alcohol Damages DNA, Increases Risk of Developing 7 Types of Cancer

Professor Ketan Patel works in the lab at MRC Laboratory of Molecular Biology in Cambridge, Britain January 2, 2018. Picture taken January 2, 2018. REUTERS/Chris Radburn
Professor Ketan Patel works in the lab at MRC Laboratory of Molecular Biology in Cambridge, Britain January 2, 2018. Picture taken January 2, 2018. REUTERS/Chris Radburn
TT
20

Alcohol Damages DNA, Increases Risk of Developing 7 Types of Cancer

Professor Ketan Patel works in the lab at MRC Laboratory of Molecular Biology in Cambridge, Britain January 2, 2018. Picture taken January 2, 2018. REUTERS/Chris Radburn
Professor Ketan Patel works in the lab at MRC Laboratory of Molecular Biology in Cambridge, Britain January 2, 2018. Picture taken January 2, 2018. REUTERS/Chris Radburn

Drinking alcohol produces a harmful chemical in the body which can lead to permanent genetic damage in the DNA of stem cells, increasing the risk of cancer developing, according to research published on Wednesday.

Working with mice in a laboratory, British scientists used chromosome analysis and DNA sequencing to examine the genetic damage caused by acetaldehyde, a harmful chemical produced when the body processes alcohol.

Their findings offered more detail about how alcohol increases the risk of developing 7 types of cancer, including common forms such as breast and bowel cancer. It also showed how the body seeks to defend against the damage alcohol can do.

“Some cancers develop due to DNA damage in stem cells. While some damage occurs by chance, our findings suggest that drinking alcohol can increase the risk of this damage,” said Ketan Patel, a professor at the Medical Research Council Laboratory of Molecular Biology, who co-led the study.

The World Health Organization’s International Agency for Research on Cancer classifies alcohol as a Group 1 carcinogen, citing “convincing evidence” it causes cancer in humans.
A study published in 2011 found that alcohol is responsible for around 4 percent of all cancer in Britain - equating to around 12,800 cases a year.

In Wednesday’s study, published in the journal Nature, Patel’s team gave diluted alcohol to mice and then analyzed the effect on the animals’ DNA. They found that acetaldehyde can break and damage DNA within blood stem cells, permanently altering the DNA sequences within these cells.

This is important, Patel said, because when healthy stem cells become faulty, they can give rise to cancerous cells.

The researchers also looked at how the body tries to protect itself against damage caused by alcohol. The first line of defense is a group of enzymes called aldehyde dehydrogenases or ALDHs, Patel explained. These break down the acetaldehyde into acetate, which cells can then use as a source of energy.

In the study, when mice lacking a critical ALDH enzyme were given alcohol, their DNA suffered four times as damage compared with mice with a properly functioning version of the enzyme.
Patel said cells also have a second line of defense in the form of a range of DNA repair systems which, most of the time, allow them to fix and reverse different types of DNA damage.

But in some instances and in some people - particularly people from South East Asia - the repair systems fail to work, meaning their cells are unable to repair effectively.

“It’s important to remember that alcohol clearance and DNA repair systems are not perfect, and alcohol can still cause cancer in different ways - even in people whose defense mechanisms are intact,” Patel said.



Gilead's Breast Cancer Drug Fails to Meet Main Goal of Late-stage Study

Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
TT
20

Gilead's Breast Cancer Drug Fails to Meet Main Goal of Late-stage Study

Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo

Gilead Sciences said on Friday its breast cancer drug Trodelvy did not significantly lower the risk of disease progression in patients when used as a first-line treatment, failing to meet the main goal of a late-stage study, Reuters reported.

Gilead said an early trend for extending overall survival, a key measure of treatment efficacy, was observed favoring patients treated with Trodelvy, compared to chemotherapy.

The data for overall survival, however, was not mature at the time of the primary analysis, the company said, adding that the study will continue to assess this secondary goal.

Trodelvy was being tested in patients with HR+/HER2-negative metastatic breast cancer, the most common subtype of the cancer, as a first-line treatment following hormone therapy.


Dubai Hookah Maker AIR to Go Public in US

Smoking paraphernalia is seen during the "Expocannabis" fair on its opening day in Leganes, outside Madrid, January 26, 2007. REUTERS/Susana Vera
Smoking paraphernalia is seen during the "Expocannabis" fair on its opening day in Leganes, outside Madrid, January 26, 2007. REUTERS/Susana Vera
TT
20

Dubai Hookah Maker AIR to Go Public in US

Smoking paraphernalia is seen during the "Expocannabis" fair on its opening day in Leganes, outside Madrid, January 26, 2007. REUTERS/Susana Vera
Smoking paraphernalia is seen during the "Expocannabis" fair on its opening day in Leganes, outside Madrid, January 26, 2007. REUTERS/Susana Vera

Dubai's AIR, the owner of hookah brand Al Fakher, said on Friday it had agreed to go public in the US through a merger with blank-check firm Cantor Equity Partners III, in a deal valuing the combined company at $1.75 billion.

The special purpose acquisition deal comes as this unconventional route to the public markets has regained popularity in the United States after years of subdued activity, following poor share performance and regulatory roadblocks.

Hookah use has grown in the US in recent years as lounges and cafes offering flavored smoking become more common, frequented by younger consumers in urban areas.While the product is often marketed as a social or cultural activity, US health agencies continue to warn that hookah smoke contains many of the same harmful chemicals found in cigarettes.

A SPAC is a shell firm that raises money through an IPO to merge with a private business and take it public, offering companies an alternative route to the market bypassing the longer and costlier traditional IPO process.

Dubai-based AIR said it generated $375 million in revenue and $150 million in adjusted earnings before interest, taxes, depreciation, and amortization for its core products in 2024.

It has eight production facilities across the United Arab Emirates, the European Union and third-party partners, supporting more than 90 markets globally with established distribution networks, the company said.

Al Fakher, its most valuable business, makes flavored hookah and had 14 million consumers worldwide as of 2024.American financial services firm Cantor Fitzgerald is the backer of the SPAC taking AIR public.

A total of 116 SPACs have completed initial public offerings so far this year, according to SPAC Research, compared with 57 in 2024.

The companies expect the deal to close in the first half of 2026, after which the combined entity, AIR Global Limited, will trade on the Nasdaq under the "AIIR" ticker symbol.


James Bond Fantasist Jailed for 7 Years in UK for Trying to Spy for Russia

Actor Daniel Craig poses for photographers on the red carpet at the German premiere of the new James Bond 007 film "Spectre" in Berlin, Germany, October 28, 2015. (Reuters)
Actor Daniel Craig poses for photographers on the red carpet at the German premiere of the new James Bond 007 film "Spectre" in Berlin, Germany, October 28, 2015. (Reuters)
TT
20

James Bond Fantasist Jailed for 7 Years in UK for Trying to Spy for Russia

Actor Daniel Craig poses for photographers on the red carpet at the German premiere of the new James Bond 007 film "Spectre" in Berlin, Germany, October 28, 2015. (Reuters)
Actor Daniel Craig poses for photographers on the red carpet at the German premiere of the new James Bond 007 film "Spectre" in Berlin, Germany, October 28, 2015. (Reuters)

A British man who would "dream about being like James Bond" was jailed Friday for seven years after trying to spy for Russia.

Howard Phillips, 65, was found guilty in July for trying to pass information about former Defense Secretary Grant Shapps, who he knew, to two men who he believed were Russian intelligence agents. However, the ‘agents’ were undercover British intelligence agents, The AP news reported.

“You were prepared to betray your country for money,” Justice Bobbie Cheema-Grubb told Phillips at his sentencing hearing at Winchester Crown Court, in the south of England.

The judge said that Phillips had “a personality with narcissistic tendencies and an overblown sense of his own importance."

The trial heard that Phillips intended to assist Russian agents between the end of 2023 and May 2024 — Shapps was defense secretary between August 2023 and July 2024 when his Conservative Party was ousted from power and he lost his seat in Parliament at the general election.

Specifically, the trial heard how Phillips had tried to hand over Shapps’ contact details as well as the location where he kept his private plane to “facilitate the Russians in listening on British defense plans.”

The defendant’s ex-wife told the court that Phillips “would dream about being like James Bond,” and watched films about the British secret services because he was “infatuated with it.”

In a victim impact statement read to the court, Shapps expressed his shock at learning of Phillips’ activities. He recalled going to dinner at Phillips' home in 2002.

“What is unacceptable is one individual’s reckless behavior exposing my entire family to the extremely serious risks that come from a foreign intelligence service’s activities," he said.

Bethan David, head of the Crown Prosecution Service’s Counter Terrorism Division, said the conviction sends “a clear message to anyone considering spying for or assisting Russia.”